NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

DARE

Dare Bioscience Inc

Jul 03 • 03:47PM ET

2.40

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: MDGL VKTX EPIX IGC AIM TVRD SEDG VTGN ADMA BPMC

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	1.59%	Shs Outstand	8.85M	Perf Week	-8.75%
Market Cap	21.24M	Forward P/E	-	EPS next Y	-0.97	Insider Trans	0.00%	Shs Float	8.71M	Perf Month	-22.33%
Enterprise Value	19.32M	PEG	-	EPS next Q	-0.52	Inst Own	9.34%	Short Float	0.53%	Perf Quarter	-17.53%
Income	-3.60M	P/S	11.30	EPS this Y	-308.85%	Inst Trans	6.47%	Short Ratio	1.84	Perf Half Y	-25.70%
Sales	1.88M	P/B	-	EPS next Y	50.40%	ROA	-16.72%	Short Interest	0.05M	Perf YTD	-23.08%
Book/sh	-1.08	P/C	2.06	EPS next 5Y	-	ROE	-	52W High	4.60 -47.83%	Perf Year	-36.68%
Cash/sh	1.17	P/FCF	-	EPS past 3/5Y	60.25% 47.17%	ROIC	-	52W Low	2.35 2.12%	Perf 3Y	-84.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.56%	Volatility	3.69% 4.34%	Perf 5Y	-80.58%
Dividend TTM	-	EV/Sales	10.28	EPS Y/Y TTM	92.45%	Oper. Margin	-1229.30%	ATR (14)	0.11	Perf 10Y	-99.59%
Dividend Ex-Date	-	Quick Ratio	0.56	Sales Y/Y TTM	88.13%	Profit Margin	-191.61%	RSI (14)	30.40	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	0.56	EPS Q/Q	17.66%	SMA20	-14.58%	Beta	1.11	Target Price	13.00
Payout	-	Debt/Eq	-	Sales Q/Q	-98.59%	SMA50	-16.76%	Rel Volume	0.41	Prev Close	2.40
Employees	23	LT Debt/Eq	-	Earnings	May 13 AMC	SMA200	-24.06%	Avg Volume	24.95K	Price	2.40
IPO	Apr 10, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	13.79% -95.77%	Trades		Volume	10,232	Change	0.00%

Jun-12-25 05:00PM	Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
05:00PM	Dare Bioscience Announces Adjournment of Annual Meeting of Stockholders (GlobeNewswire)
Jun-06-25 09:40AM	Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-04-25 08:00AM	Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Darés DARE to PLAY Sildenafil Cream (GlobeNewswire)
08:00AM	Dare Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Dare's DARE to PLAY Sildenafil Cream (GlobeNewswire)
12:53PM	Loading…
May-14-25 12:53PM	Q1 2025 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents)
03:14AM	Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ... (GuruFocus.com)
May-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update (GlobeNewswire)
04:01PM	Dare Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update (GlobeNewswire)
May-12-25 05:25PM	Acadia Healthcare (ACHC) Beats Q1 Earnings Estimates (Zacks)
May-08-25 06:10PM	Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 08:00AM	Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 (GlobeNewswire)
08:00AM	Dare Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 (GlobeNewswire)
Apr-23-25 08:00AM	Dar Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation (GlobeNewswire)
08:00AM	Loading…
08:00AM	Dare Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women's Health Innovation (GlobeNewswire)
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Apr-07-25 08:00AM	Dar Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year (GlobeNewswire)
Apr-01-25 09:56AM	Q4 2024 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Mar-31-25 10:14PM	Dare Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript (Seeking Alpha)
05:15PM	Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Dare Bioscience Reports Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
04:01PM	Dar Bioscience Reports Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
Mar-24-25 08:00AM	Dare Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 (GlobeNewswire)
08:00AM	Dar Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 (GlobeNewswire)
Feb-20-25 08:00AM	Dar Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant (GlobeNewswire)
Feb-06-25 08:00AM	Dare Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development (GlobeNewswire)
08:00AM	Dar Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development (GlobeNewswire)
Jan-09-25 08:00AM	Dare Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
08:00AM	Dar Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 08:00AM	Dare Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) (GlobeNewswire)
08:00AM	Dar Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) (GlobeNewswire)
Dec-10-24 08:00AM	Dar Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% (GlobeNewswire)
Dec-04-24 08:00AM	Dare Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
08:00AM	Dar Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
Nov-15-24 01:54PM	Q3 2024 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents) -9.96%
02:19AM	Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Nov-14-24 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.04%
04:01PM	Dare Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
04:01PM	Dar Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Nov-13-24 08:00AM	Dare Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene Pivotal Study Clinical Trial Sites (GlobeNewswire) -13.04%
08:00AM	Dar Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene Pivotal Study Clinical Trial Sites (GlobeNewswire)
Nov-07-24 12:00PM	Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know (Zacks)
08:00AM	Dare Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 (GlobeNewswire)
08:00AM	Dar Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 (GlobeNewswire)
Oct-23-24 12:30PM	Dare Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health (GlobeNewswire)
12:30PM	Dar Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health (GlobeNewswire)
Oct-21-24 08:05AM	Dare Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC (GlobeNewswire)
08:05AM	Dar Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC (GlobeNewswire)
Aug-26-24 08:00AM	Dar Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% (GlobeNewswire)
Aug-13-24 08:00AM	Dare Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% (GlobeNewswire) +20.00%
08:00AM	Dar Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% (GlobeNewswire)
Aug-12-24 05:15PM	Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates (Zacks)
04:01PM	Dare Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
04:01PM	Dar Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
Aug-05-24 08:00AM	Dar Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 (GlobeNewswire)
Jul-19-24 08:00AM	Dare Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) +10.97%
08:00AM	Dar Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Jul-01-24 06:54AM	Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors (Newsfile) -6.03%
Jun-27-24 08:00AM	Dare Bioscience Announces Reverse Stock Split (GlobeNewswire) -14.56%
08:00AM	Dar Bioscience Announces Reverse Stock Split (GlobeNewswire)
Jun-24-24 08:00AM	Dare Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder (GlobeNewswire)
08:00AM	Dar Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder (GlobeNewswire)
May-15-24 12:27PM	Q1 2024 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents) +14.29%
03:13AM	Dare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid ... (GuruFocus.com)
May-14-24 12:53PM	DARE Stock Earnings: Dare Bioscience Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Dar Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update (GlobeNewswire)
May-07-24 08:00AM	Dar Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 (GlobeNewswire)
May-02-24 08:00AM	Dare Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network (GlobeNewswire) -5.43%
08:00AM	Dar Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network (GlobeNewswire)
Apr-30-24 07:30AM	Dare Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts (GlobeNewswire) +9.08%
07:30AM	Dar Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts (GlobeNewswire)
Apr-23-24 08:00AM	Dare Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
08:00AM	Dar Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 (GlobeNewswire)
Apr-11-24 08:00AM	Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive (GlobeNewswire)
Apr-01-24 04:05PM	Dar Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:07AM	Q4 2023 Dare Bioscience Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 01:53PM	DARE Stock Earnings: Dare Bioscience Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -10.71%
08:00AM	Dar Bioscience Reports Full Year 2023 Financial Results and Provides Company Update (GlobeNewswire)
Mar-21-24 08:00AM	Dare Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 (GlobeNewswire)
08:00AM	Dar Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 (GlobeNewswire)
Feb-22-24 08:00AM	Dare Bioscience to Present at the International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting (GlobeNewswire) +21.61%
Jan-31-24 08:00AM	Dare Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024 (GlobeNewswire)
Jan-26-24 04:30PM	Dare Bioscience Announces Executive Team and Board of Directors Changes (GlobeNewswire) +5.14% -9.09%
Jan-17-24 08:00AM	Dar Bioscience Announces Grant to Support Biotherapeutic Product Development (GlobeNewswire)
Jan-04-24 08:00AM	Dare Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases (GlobeNewswire) +10.24%
Dec-26-23 08:00AM	Dar Bioscience Secures $12 million in Royalty-backed Investment Structure (GlobeNewswire)
Dec-20-23 08:00AM	Dare Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study (GlobeNewswire)
Dec-13-23 08:00AM	Dar Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study (GlobeNewswire)
Dec-07-23 08:00AM	Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause (GlobeNewswire) -7.89%
Dec-04-23 08:00AM	Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive (GlobeNewswire)
Nov-23-23 03:38PM	20 Countries with the Highest Teenage Pregnancy Rates (Insider Monkey)
Nov-20-23 08:00AM	Dar Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Dar 's Novel Women's Health Programs (GlobeNewswire)
Nov-13-23 08:00AM	Dar Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting (GlobeNewswire) +5.79%
Nov-10-23 10:16AM	Dar Bioscience, Inc. (NASDAQ:DARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 08:00AM	Dar Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update (GlobeNewswire) -6.93%
Nov-06-23 08:00AM	Dar Bioscience to Participate in Three November Conferences (GlobeNewswire) -8.63%
Nov-02-23 08:00AM	Dar Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023 (GlobeNewswire)
Nov-01-23 08:00AM	Dar Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program (GlobeNewswire)

Dare Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DARE

Dare Bioscience Inc

Upgrade your FINVIZ experience